Bullish & Foolish
Full GOVX fundamentals All 466 on the Survival Watch

GOVXGEOVAX LABS, INC.

Is Geovax Labs struggling financially?

Yes, by its own account. Geovax Labs told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Grant funding

    In April 2025, we were notified that BARDA elected to terminate the contract for convenience, consistent with its terms. There were therefore no revenues reported during the March 2026 period.

    Form 10-Q, filed 14 May 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$4.8M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 3months

    If it eases off

    Empty by Sep 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$3.1M

÷

Cash burned over the last 12 months

$21.5M

What Geovax Labs told the SEC

…or from other sources. There can be no assurance that additional funding will be available on favorable terms or at all. These factors collectively raise substantial doubt about the Company’s ability to continue as a going concern. Management believes that we will be successful in securing the additional capital required to continue the Company’s planned operations, but that our plans do not fully alleviate the…

GEOVAX LABS, INC., Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • Cash burn is narrowing It is spending 48% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt